C92.4

Clinical Causes: Genetic mutations, particularly the translocation t(15;17), which results in the fusion of the PML and RAR-alpha genes. This chromosomal change leads to abnormal development and accumulation of promyelocytes. Environmental exposures such as prior chemotherapy or radiation therapy may contribute, but these are less common factors. In some cases, the exact cause of APML remains unknown, with genetic factors playing a significant role.

Key Symptoms: Fatigue and weakness due to anemia Bleeding and easy bruising caused by low platelet levels Fever and infections resulting from reduced healthy white blood cells Sores or petechiae (small red or purple spots on the skin) Shortness of breath and dizziness Unusual or excessive bleeding, including gum bleeding or blood in urine or stool Potential swelling or pain in the abdomen if the spleen or liver is affected

Diagnosis Path: Diagnosis of acute promyelocytic leukemia typically involves a combination of blood tests and bone marrow examinations. Key diagnostic steps include: - Complete blood count (CBC) to evaluate levels of red cells, white blood cells, and platelets. - Peripheral blood smear to observe abnormal promyelocytes. - Bone marrow biopsy, which confirms the presence of leukemia cells. - Cytogenetic analysis to detect the t(15;17) translocation. - Molecular testing, such as PCR, to identify the PML-RAR-alpha fusion gene. Early and accurate diagnosis is crucial for effective management and treatment planning.

Treatment Protocols: Treatment of APML has advanced significantly and typically involves a combination of therapies: - All-trans retinoic acid (ATRA): A targeted drug that induces the differentiation of leukemia cells. - Chemotherapy agents: Often combined with ATRA to eliminate remaining leukemia cells. - Arsenic trioxide: Used in some cases, particularly for relapsed or refractory disease. - Supportive care: Includes transfusions, antibiotics, and growth factors to manage side effects and complications. - Monitoring: Regular tests to assess response to treatment and detect remission status. The prognosis for patients with APML has improved greatly, with many achieving complete remission, especially when diagnosed early and treated appropriately.